Advertisement

Related Videos

Opening Session Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Jul
12
Today In Oncology
ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers
FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer
Long-Term Overall Survival With Addition of SBRT to Abiraterone Acetate and ADT in Oligometastatic Castration-Resistant Prostate Cancer
FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo